MINNEAPOLIS and WASHINGTON, April 20,
2015 /PRNewswire/ -- Inspire Medical Systems, Inc.,
announced today that a scientific paper on its Inspire Upper Airway
Stimulation (UAS) therapy for obstructive sleep apnea (OSA), has
been recognized with a Top 10 Clinical Research Achievement Award
from the Clinical Research Forum. The awards were announced at the
Forum's Annual Meeting in Washington,
D.C. The 10 winning papers were chosen based on their degree
of innovation from a pool of more than 50 nominations from 30
research and academic health centers nationwide.
Submitted by researchers at the University
of Pittsburgh Medical Center and University Hospitals in
Cleveland, the paper "Upper-Airway
Stimulation for Obstructive Sleep Apnea," showed that implanting
Inspire therapy led to a 68 percent reduction in sleep apnea events
and significant improvements in quality of life measures. The paper
includes findings from Inspire Medical System's Stimulation for
Apnea Reduction (STAR) trial, the results of which were published
January 9, 2014, in the New
England Journal of Medicine.
"Findings from the STAR trial were a crucial part of the FDA
assessment and approval process for Inspire therapy," said
Tim Herbert, CEO of Inspire Medical
Systems. "We are honored to have the publication of our pivotal
trial results recognized by the Clinical Research Forum and would
like to thank the exceptional team of independent researchers,
and in particular the lead investigators, for their dedication
and hard work."
Inspire therapy is an implantable device approved to
treat people with moderate to severe OSA who are unable to use
Continuous Positive Airway Pressure (CPAP) therapy. While CPAP is
often successful, studies show that roughly half of all patients
that start CPAP eventually become non-compliant.
The Clinical Research Forum's Top 10 Clinical Research
Achievement Awards honor outstanding accomplishments in
clinical research. This annual national competition seeks to
identify major advances resulting from the nation's investment in
research to benefit the health and welfare of its citizens.
About Inspire therapy
InspireĀ® Upper Airway
Stimulation (UAS) is an FDA approved treatment for people with
moderate to severe OSA who are unable to use CPAP. Inspire therapy
is a fully implanted system consisting of three components: a small
generator, a sensing lead and a stimulation lead. The single
external component, a small handheld Inspire sleep remote, is used
to turn the therapy on before bed and off upon waking. When
activated, Inspire therapy senses breathing patterns and delivers
mild stimulation to key airway muscles, which keeps the airway open
during sleep. Patients implanted with Inspire therapy who
participated in the STAR (Stimulation Therapy for Apnea Reduction)
pivotal clinical trial experienced a 68 percent reduction in apnea
events, a 70 percent reduction in oxygen desaturation events, and
significant improvements in Quality of Life. These results were
published in the January 9, 2014,
issue of the New England Journal of Medicine. For more
information visit:
http://www.multivu.com/mnr/7169651-fda-approves-inspire-upper-airway-stimulation-therapy-sleep-apnea
About Inspire Medical Systems, Inc.
Inspire Medical
Systems, Inc., based in Minneapolis,
Minn., was formed in 2007 when the technology and a
significant intellectual property portfolio was spun-out of
Medtronic (NYSE: MDT). Inspire Medical Systems has
developed an FDA approved, implantable neurostimulation system
for the treatment of Obstructive Sleep Apnea (OSA). Privately held,
investors include Aperture Venture Partners, GDN Holdings, Johnson
& Johnson Development Corporation, Kleiner Perkins Caufield & Byers, Medtronic,
OrbiMed Advisors, Synergy Life Science Partners, TGap Ventures and
US Venture Partners. Visit Inspire Medical Systems on the web at
www.inspiresleep.com.
About the Clinical Research Forum
Formed in 1996, the
Clinical Research Forum convenes annually to allow industry leaders
to discuss issues facing the field, best practices, and promote
understanding and support for clinical research and its impact on
health and healthcare. Through its activities, the Forum has
increasingly played a national advocacy role in supporting broader
interests and needs of clinical research. You can find more
information at www.clinicalresearchforum.org.
Media contacts:
Helen Shik or Rachel Gross
MSLGROUP Boston
781-684-0770
InspireMedical@mslgroup.com
Logo - http://photos.prnewswire.com/prnh/20140514/87756
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/study-of-upper-airway-stimulation-uas-therapy-for-sleep-apnea-named-a-top-ten-outstanding-research-paper-300068057.html
SOURCE Inspire Medical Systems, Inc.